Prophylactic application of fluoroquinolones for selective decontamination of the gut: Friend or foe

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 24, Issue 2, 2005, Pages 109-110

  Van Belkum, A ^a   Vos, M C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT;

DRUG EFFICACY; EDITORIAL; ENTEROBACTERIACEAE; GENOTYPE; GRAM POSITIVE BACTERIUM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTESTINE; INTESTINE FLORA; INTESTINE INFECTION; LEUKEMIA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS;

ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FLUOROQUINOLONES; HUMANS; IMMUNOCOMPROMISED HOST; INTESTINES;

EID: 16844383969     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-005-1282-1     Document Type: Editorial

References (22)

1. Trifilio S, Verma A, Mehta J (2004) Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant 33:735-739
2. Klastersky J (1998) Science and pragmatism in the treatment and prevention of infections in neutropenic patients. J Antimicrob Chemother 41:13-24
3. Hughes WT, Armstrong B, Bodey GP, et al (2002) Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730-751
4. Cruciani M, Rampazzo R, Malena M, et al (1996) Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta analysis. Clin Infect Dis 23:795-805
5. Engels EA, Lau J, Barza M (1998) Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta analysis. J Clin Oncol 16:1179-1189
6. Rotstein CML, Goldberg N (1997) Fluoroquinolone prophylaxis for profoundly neutropenic cancer patients: a meta analysis. Curr Opin Oncol 4:S2-S7
7. Lingnau W, Berger J, Javorsky F, Fille M, Allerberger F, Benzer H (1998) Changing bacterial ecology during a five-year period of selective intestinal decontamination. J Hosp Infect 39:195-206
8. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F ( 1995) Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 20:557-560
9. Patrick CC (1997) Use of fluoroquinolones as prophylactic agents in patients with deep neutropenia. Pediatr Infect Dis J 16:135-139
10. Baum HV, Franz U, Geiss HK (2000) Prevalence of ciprofloxacin resistant Escherichia coli in hemato-oncologic patients. Infection 28:259-260
11. Cruciani M (2004) Adding gram-positive prophylaxis to fluoroquinolone regimens reduces streptococcal bacteraemias, but prophylaxis remains controversial. Cancer Treat Rev 30:385-388
12. Zinner SH (1999) Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 29:490-494
13. Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P, Reuter S, Von Baum H, Marre R (2004) Fluoroquinolone resistance of Escherichia coli at a cancer center: epidmiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis (current issue)
14. Gomez L, Garau J, Estrada C, Marquez M, Dalmau D, Xercavins M, Marti JM, Estany C (2003) Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with high prevalence of ciprofloxacin-resistant Escherichia coli. Cancer 97:419-424
15. Martino R, Subira M, Altes A, Lopez R, Sureda A, Domingo-Albos A, Pericas R, Bmnet S (1998) Effect of discontinuing prophylaxis with norfloxacin in patients with hematological malignancies and severe neutropenia. A matched case-control study on the effect of infectious morbidity. Acta Haematol 99:206-211
16. Van Belkum A, Goessens W, Van der Schee C, Lemmens den Toom N, Vos MC, Cornelissen J, Lugtenburg E, De Marie S, Verbrugh H, Lowenberg B, Endtz H (2001) Rapid emergence of ciprofloxacin-resistant enterobacteriaceae containing multiple gentamicin resistance-associated integrons in a Dutch hospital. Emerg Infect Dis 7:862-871
17. Bosi C, Davin Regli A, Bornet C, Mallea M, Pages JM, Bollet C ( 1999) Most Enterobacter aerogenes strains in France belong to a prevalent clone. J Clin Microbiol 37:2165-2169
18. Ronveaux O, De Gheldre Y, Glupczynski Y, Struelens M, De Mol P (2000) Emergence of Enterobacter aerogenes as a major antibiotic-resistant nosocomial pathogen in Belgian hospitals. Clin Microbiol Infect 5:622-627
19. Kroschinsky F, Wichmann G, Bornhauser M, Ordemann R, Schule G, Hanel M (2002) Efficacy and tolerability of prophylactic treatment with intravenous piperacillin/tazobactam in patients undergoing hematopoietic stem cell transplantation. Transpl Infect Dis 4:132-136
20. Razonable RR, Litzow MR, Khaliq Y, Piper KE, Rouse MS, Patel R (2002) Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis 34:1469-1474
21. Lee DG, Choi SM, Choi JH, Yoo JH, Park YH, Kim YJ, Lee S, Min HG, Kim DW, Lee JW, Min WS, Shin WS, Kim CC (2002) Selective bowel decontamination for the prevention of infections during myelogenous leukemia: a prospective randomised trial. Korean J Intern Med 17:38-44
22. Prabhu RM, Elliott MA, Patel R (2004) Apparent failure of moxifloxacin to prevent ciprofloxacin- and levofloxain-susceptible Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation. Clin Infect Dis 38:1043-1045